MX376639B - Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer. - Google Patents

Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.

Info

Publication number
MX376639B
MX376639B MX2018005725A MX2018005725A MX376639B MX 376639 B MX376639 B MX 376639B MX 2018005725 A MX2018005725 A MX 2018005725A MX 2018005725 A MX2018005725 A MX 2018005725A MX 376639 B MX376639 B MX 376639B
Authority
MX
Mexico
Prior art keywords
sup
cancer
treatment
derivatives useful
dihydroimidazopyrazinone
Prior art date
Application number
MX2018005725A
Other languages
English (en)
Other versions
MX2018005725A (es
Inventor
Andrew Hornby Dobson
Clifford David Jones
James Francis Mccabe
Mark Andrew Graham
Richard Andrew Ward
Steven Swallow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018005725A publication Critical patent/MX2018005725A/es
Publication of MX376639B publication Critical patent/MX376639B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a compuestos de Fórmula (I) (ver Fórmula) o sales farmacéuticamente aceptables de los mismos, en la que R1, R2 y R3 tienen cualquiera de los significados definidos anteriormente en el presente documento en la descripción; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento del cáncer.
MX2018005725A 2015-11-09 2016-11-08 Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer. MX376639B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252726P 2015-11-09 2015-11-09
US201662401351P 2016-09-29 2016-09-29
PCT/EP2016/076932 WO2017080979A1 (en) 2015-11-09 2016-11-08 Dihydroimidazopyrazinone derivatives useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2018005725A MX2018005725A (es) 2018-08-14
MX376639B true MX376639B (es) 2025-03-07

Family

ID=57241113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005725A MX376639B (es) 2015-11-09 2016-11-08 Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.

Country Status (35)

Country Link
US (2) US9902731B2 (es)
EP (1) EP3374359B1 (es)
JP (1) JP6877423B2 (es)
KR (1) KR20180074788A (es)
CN (1) CN108349983B (es)
AU (1) AU2016351813B2 (es)
BR (1) BR112018008397B1 (es)
CA (1) CA3003549A1 (es)
CL (1) CL2018001226A1 (es)
CO (1) CO2018004857A2 (es)
CR (1) CR20180316A (es)
CY (1) CY1123627T1 (es)
DK (1) DK3374359T3 (es)
EA (1) EA038028B1 (es)
ES (1) ES2780650T3 (es)
HR (1) HRP20200342T1 (es)
IL (1) IL258953A (es)
LT (1) LT3374359T (es)
ME (1) ME03770B (es)
MX (1) MX376639B (es)
MY (1) MY197626A (es)
NI (1) NI201800058A (es)
PE (1) PE20181288A1 (es)
PH (1) PH12018500987A1 (es)
PL (1) PL3374359T3 (es)
PT (1) PT3374359T (es)
RS (1) RS60155B1 (es)
SG (1) SG11201803066VA (es)
SI (1) SI3374359T1 (es)
SM (1) SMT202000152T1 (es)
SV (1) SV2018005687A (es)
TN (1) TN2018000119A1 (es)
TW (1) TWI730012B (es)
WO (1) WO2017080979A1 (es)
ZA (1) ZA201803742B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2989326T3 (es) 2015-10-21 2024-11-26 Otsuka Pharma Co Ltd Compuestos de benzolactama como inhibidores de la proteína cinasa
WO2017080979A1 (en) * 2015-11-09 2017-05-18 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
EP3845538B1 (en) * 2018-10-10 2023-11-08 Shenzhen TargetRx, Inc. Dihydroimidazopyrazinone compound, composition including same, and use thereof
JP2022527744A (ja) 2019-03-28 2022-06-06 ジエンス ヘンルイ メデイシンカンパニー リミテッド チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用
JP2022534224A (ja) 2019-05-24 2022-07-28 江蘇恒瑞医薬股▲ふん▼有限公司 置換縮合二環式誘導体、その調製方法、および医薬におけるその適用
KR102936514B1 (ko) * 2019-06-06 2026-03-09 허치메드 리미티드 트리사이클릭 화합물 및 이의 용도
EP4069687B1 (en) 2019-12-05 2024-01-31 Astrazeneca AB Process and intermediates for the production of formula (i)
EP4071155A4 (en) * 2019-12-06 2024-01-17 D3 Bio (Wuxi) Co., Ltd. THIAZOLOLACTAM COMPOUND USED AS ERK INHIBITOR AND USE THEREOF
AU2021354821A1 (en) 2020-09-29 2023-06-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
CN117529321A (zh) * 2021-06-18 2024-02-06 上海德琪医药科技有限公司 Erk抑制剂和kras抑制剂的组合及其用途
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors
CA3227706A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2023081857A1 (en) 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Condensed pyridazine amine derivatives treating sca3
EP4514807B1 (en) 2022-04-27 2025-12-17 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
EP4522624A1 (en) 2022-05-12 2025-03-19 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US7485640B2 (en) * 2002-11-06 2009-02-03 Merck Sharp & Dohme Limited Imidazopyrazinones as GABA-A receptor anxiolytics
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
BR112013015430A2 (pt) * 2010-12-22 2016-09-20 Janssen Pharmaceutica Nv derivados de 5,6-diidro-imidazo[1,2-a]pirazin-8-ilamina úteis como inibidores de beta-secretase (bace)
HK1211023A1 (zh) * 2011-10-10 2016-05-13 H. Lundbeck A/S 具有咪唑并吡嗪骨架pde9i
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
DK3321262T3 (da) 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AU2014360455B2 (en) 2013-12-06 2018-05-10 Genentech, Inc. Serine/threonine kinase inhibitors
EP3089980B1 (en) 2013-12-30 2018-01-31 Array Biopharma, Inc. Serine/threonine kinase inhibitors
BR112016015235A2 (pt) 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
HRP20191306T1 (hr) 2014-04-09 2019-10-18 Genentech, Inc. Postupak proizvodnje lijekova
US10412619B2 (en) * 2014-11-14 2019-09-10 Qualcomm Incorporated Buffer status report for eDCS
WO2016162325A1 (en) * 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
CN107849046B (zh) 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
CA2987963C (en) 2015-06-03 2023-01-24 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
WO2017080979A1 (en) * 2015-11-09 2017-05-18 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer

Also Published As

Publication number Publication date
US10202391B2 (en) 2019-02-12
TWI730012B (zh) 2021-06-11
US20180237443A1 (en) 2018-08-23
DK3374359T3 (da) 2020-03-30
SMT202000152T1 (it) 2020-05-08
EA038028B1 (ru) 2021-06-24
TN2018000119A1 (en) 2019-10-04
CR20180316A (es) 2018-10-05
HK1256283A1 (en) 2019-09-20
AU2016351813A1 (en) 2018-06-21
BR112018008397A2 (pt) 2018-10-23
PT3374359T (pt) 2020-03-27
PL3374359T3 (pl) 2020-06-29
EP3374359A1 (en) 2018-09-19
MX2018005725A (es) 2018-08-14
HRP20200342T1 (hr) 2020-06-12
US20170204100A1 (en) 2017-07-20
RS60155B1 (sr) 2020-05-29
MY197626A (en) 2023-06-29
CY1123627T1 (el) 2022-03-24
EA201891063A1 (ru) 2018-12-28
TW201728586A (zh) 2017-08-16
JP2019503337A (ja) 2019-02-07
SV2018005687A (es) 2018-07-20
US9902731B2 (en) 2018-02-27
EP3374359B1 (en) 2020-01-08
ME03770B (me) 2021-04-20
NI201800058A (es) 2018-10-18
KR20180074788A (ko) 2018-07-03
CN108349983B (zh) 2021-02-26
PH12018500987A1 (en) 2019-01-28
PE20181288A1 (es) 2018-08-07
CO2018004857A2 (es) 2018-07-19
BR112018008397B1 (pt) 2023-12-12
IL258953A (en) 2018-06-28
ES2780650T3 (es) 2020-08-26
LT3374359T (lt) 2020-03-25
WO2017080979A1 (en) 2017-05-18
CL2018001226A1 (es) 2018-10-05
CN108349983A (zh) 2018-07-31
SG11201803066VA (en) 2018-05-30
CA3003549A1 (en) 2017-05-18
JP6877423B2 (ja) 2021-05-26
SI3374359T1 (sl) 2020-04-30
AU2016351813B2 (en) 2019-05-30
ZA201803742B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
MX376639B (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12015502615A1 (en) Chemical compounds
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
PH12015502159A1 (en) Chemical entities
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
TN2015000313A1 (en) Chemical compounds
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
TW201613864A (en) Novel compounds
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
TN2017000018A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases.
MX395659B (es) Compuestos triciclicos y su uso en el tratamiento del cancer

Legal Events

Date Code Title Description
FG Grant or registration